Electra Therapeutics, Inc. (ETRA) insider trading.
In Q3 2026, insiders at Electra Therapeutics, Inc. reported 16 non-derivative transactions on 18 Forms 3, 4 and 5: 4 open-market purchases worth $40.0M and 0 sales.
- Transactions
- 16
- Purchases (P)
- 4
- Sales (S)
- 0
- Net shares, P minus S
- 2,666,666
- Insiders
- 6
- Last filed
- 2026-09-23
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| OrbiMed Capital GP VII LLC / OrbiMed Genesis GP LLC / ORBIMED ADVISORS LLC | Director, TenPercentOwner | 6 | 2 | 0 |
| Gordon Carl L | Director, TenPercentOwner | 6 | 2 | 0 |
| Stagliano Nancy | Director | 1 | 0 | 0 |
| Dong Quehuong (Kathy) | Director, Officer · President & CEO | 1 | 0 | 0 |
| Koe Gary S. | Officer · Chief Technical Officer | 1 | 0 | 0 |
| Parry Graham | Officer · Chief Scientific Officer | 1 | 0 | 0 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-21 | OrbiMed Capital GP VII LLC / OrbiMed Genesis GP LLC / ORBIMED ADVISORS LLC | C (A) | 2,002,310 | — | 2,002,310 | Form 4 |
| 2026-09-21 | OrbiMed Capital GP VII LLC / OrbiMed Genesis GP LLC / ORBIMED ADVISORS LLC | C (A) | 1,703,314 | — | 4,793,558 | Form 4 |
| 2026-09-21 | OrbiMed Capital GP VII LLC / OrbiMed Genesis GP LLC / ORBIMED ADVISORS LLC | C (A) | 758,279 | — | 758,279 | Form 4 |
| 2026-09-21 | OrbiMed Capital GP VII LLC / OrbiMed Genesis GP LLC / ORBIMED ADVISORS LLC | P (A) | 1,000,000 | $15 | 1,758,279 | Form 4 |
| 2026-09-21 | OrbiMed Capital GP VII LLC / OrbiMed Genesis GP LLC / ORBIMED ADVISORS LLC | C (A) | 1,087,934 | — | 3,090,244 | Form 4 |
| 2026-09-21 | OrbiMed Capital GP VII LLC / OrbiMed Genesis GP LLC / ORBIMED ADVISORS LLC | P (A) | 333,333 | $15 | 5,126,891 | Form 4 |
| 2026-09-21 | Gordon Carl L | P (A) | 333,333 | $15 | 5,126,891 | Form 4 |
| 2026-09-21 | Gordon Carl L | C (A) | 1,703,314 | — | 4,793,558 | Form 4 |
| 2026-09-21 | Gordon Carl L | P (A) | 1,000,000 | $15 | 1,758,279 | Form 4 |
| 2026-09-21 | Gordon Carl L | C (A) | 1,087,934 | — | 3,090,244 | Form 4 |
| 2026-09-21 | Gordon Carl L | C (A) | 2,002,310 | — | 2,002,310 | Form 4 |
| 2026-09-21 | Gordon Carl L | C (A) | 758,279 | — | 758,279 | Form 4 |
| 2026-09-21 | Stagliano Nancy | C (A) | 255,635 | — | 255,635 | Form 4 |
| 2026-09-21 | Dong Quehuong (Kathy) | C (A) | 455,484 | — | 455,484 | Form 4 |
| 2026-09-21 | Koe Gary S. | C (A) | 63,656 | — | 63,656 | Form 4 |
| 2026-09-21 | Parry Graham | C (A) | 85,504 | — | 85,504 | Form 4 |
Transaction codes in this quarter
Get ETRA insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=2088082&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · ETRA company page · Electra Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Electra Therapeutics, Inc. (ETRA)?
In Q3 2026, insiders at Electra Therapeutics, Inc. reported 16 non-derivative transactions on 18 Forms 3, 4 and 5: 4 open-market purchases worth $40.0M and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Electra Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/etra.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.